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SUMMARY 
Recently, the advanced breast biopsy instrumentation (ABBI) system has been introduced as an alternative to 
conventional breast biopsy techniques. This study was prospectively conducted to evaluate the potential of the 
ABBI method in locoregional management of a consecutive series of patients with nonpalpable 
mammographically detected breast carcinomas. Sixty-one consecutive patients underwent an ABBI procedure as 
a first step before possible surgery for nonpalpable breast lesions that would in any case require complete 
excision. For the 27 patients in whom the ABBI biopsy revealed malignancy further surgery was recommended, 
including re-excision of the biopsy site and axillary dissection in cases of infiltrating carcinoma. We calculated 
the probabilities that the ABBI specimen would have tumor-free margins and that a definitely complete excision 
had been achieved as a function of the mammographic or pathological diameter of the cancer. For cancer with a 
pathological diameter less than 10 mm measured on the ABBI specimen, the probability (92%) of obtaining 
complete resection was significantly better than for larger lesions (P = 0.01, Fisher's exact test). Although the 
therapeutic perspectives for the ABBI method are limited at present, we suggest that this approach is a first step 
in the direction of a surgical strategy that is better adapted to the pathological characteristics peculiar to these 
small tumors, whose incidence is increasing. 
 
INTRODUCTION 
Over the past few years, breast surgeons have been confronted with an increasing number of nonpalpable 
mammographically detected lesions. Mammograms performed in asymptomatic patients detect 0.5-2% of 
nonpalpable breast lesions (NPBL), 10-30% of which are cancers.1 At present, 30% of the breast lesions that we 
operate on in our institution are NPBL. Pathological examination of surgically excised lesions confirms an 
underlying cancer in 50% of these cases and a high-risk lesion, such as a lobular carcinoma in situ, atypical 
hyperplasia, or radial scar, in 15% of them. 
Classically, excision is guided by a hook wire placed prior to the surgical intervention. Despite the preoperative 
localization, the volume of tissue excised often exceeds the dimensions of the lesion by far still with no 
guarantee that the resection margins are tumor-free, as frozen-section evaluation of these borders is usually not 
possible.2 A few targeted lesions are not even found in the biopsy specimens.3,4
Progress in the field of endoscopic surgery suggested a way of improving the quality of the diagnostic specimen 
and also of achieving total excision of the smallest NPBL through a small incision. At the end of 1994, we felt it 
should be possible to remove a small lesion as a single tissue specimen through a large electroinsulated cannula 
inserted percutaneously and perpendicular to the targeted lesion under stereotactic control, with the patient lying 
prone on a dedicated table.5 A system coupling distal section-coagulation and traction would allow the 
subsequent en bloc excision of the lesion. The advanced breast biopsy instrumentation (ABBI) system (United 
States Surgical Corporation, Norwalk, CT, USA) incorporated this principle. This device, in conjunction with a 
stereotactic biopsy table, allows single-pass excision of cylindrical specimens of variable diameter (0.5-2 cm) 
from the subcutaneous tissue up to and beyond the targeted lesion.6 Since the FDA approval was granted for the 
ABBI as a diagnostic tool in early 1996, its feasibility, safety, accuracy and cost-benefits for the diagnostic 
management of nonpalpable lesions have been assessed.6 19
In a previous study, we evaluated the proportion of our patients in whom NPBL would have unequivocally 
required complete excision but could be adequately removed with ABBI.20 The present prospective 
nonrandomized study was conducted to evaluate the potential of the ABBI method for the locoregional 
management of a consecutive series of nonpalpable breast carcinomas. 
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MATERIALS AND METHODS 
From May 1998 to December 2000, 448 consecutive patients aged 22-80 years (mean 54) were referred for 
management of NPBL. Patients underwent either image-guided needle biopsy or an ABBI procedure. When 
feasible, an ABBI procedure was offered to patients as a first step before possible surgery for lesions which 
would definitely require complete excision: mammographic features highly suggestive of malignancy (BI-RADS 
category 5),21 suspicious abnormality (BI-RADS category 4) in the presence of high-risk factors (i.e., family or 
personal history of breast cancer, recent or growing lesion), or the patient's request for complete excision in the 
presence of a probably benign or suspicious lesion (BI-RADS category 3 or 4). Exclusion criteria for an ABBI 
procedure were: multiple lesions, mammographic diameter of the lesion larger than 15 mm, breast compressible 
to less than 25 mm, hemorrhagic diathesis, body weight over 135 kg (3001b) and inability of the patient to lie 
still for 1 h in a prone position. 
Fig. 1: (A) Principles of removing a small nonpalpable breast lesion as a single tissue specimen (E.L., 1994). The 
patient lies in the prone position (1). The breast is protruding through a central aperture in the stereotactic table (2). Each step of the 
procedure is radiologically checked (3). With the breast compressed as for mammography, a hook-wire is inserted as far as the suspicious 
lesion (4). The skin is incised and a plastic cannula is put in place beyond the targeted lesion (5). The bottom of the specimen is sectioned 
and the cannula containing the specimen is then removed from the breast (6). (B) The ABBI device allows percutaneous en bloc excision of a 
cylinder of breast tissue up to 20 mm in diameter. (C) The patient is positioned prone on a dedicated stereotactic table, and the biopsy device 
is targeted using digital stereomammography. 
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Fig. 2: (A) Spot compression view of the right breast of this 66-year-old woman confirmed a nonpalpable 6-mm 
spiculated mass. (B) Partial digital radiographs (same magnification) show the pre-biopsy view of the targeted lesion (left) and the 
biopsy cavity after the ABBI procedure using a 20-mm cannula (right). (C) Digital radiograph of the ABBI specimen shows apparently 
complete excision. Histopathological analysis confirmed a 6-mm well-differentiated infiltrating ductal carcinoma resected in sano. Surgical 
re-excision of the biopsy site confirmed the residual tumor-free status. 
 
 
All patients gave informed consent and agreed to potential subsequent surgery. Overall, 61 ABBI procedures 
were completed. Patient selection, the ABBI procedure and surgery were performed by the same investigator 
(E.L.). The ABBI procedure was performed in an outpatient setting, as previously described.6 The ABBI device 
is targeted by the dedicated stereotactic imaging unit of a prone table (United States Surgical Corporation and 
Lorad, Danbury, CT, USA) (Fig. 1A-C). Patients were each given one 0.5-mg tablet of alprazolam (Xanax, 
Pharmacia-Upjohn, Puurs, Belgium) before the procedure. The patient was positioned prone with the breast 
protruding through an opening and ECG monitoring and electrocautery contact were established. The lesion was 
targeted using digital stereomammography. Each step of the procedure was documented with digital imaging. 
The biopsy device consisted of a plastic cannula of variable diameter (5, 10, 15, 20 mm) with a rotating distal 
circular blade. We usually choose the largest diameter to obtain clear margins. The breast was surgically 
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prepared. Once deep local anesthesia (15 ml of 1% lidocaine with epinephrine) was achieved, a guide wire was 
inserted proximal to the targeted lesion, after which the cannula was introduced through a skin incision 5 mm 
larger than the cannula diameter and advanced 10-15 mm beyond the center of the lesion. Correct positioning 
was confirmed by stereomammography. An electrocautery snare at the distal end of the cannula cut and 
cauterized the deep end of the specimen. The device was removed together with the enclosed specimen. Digital 
radiographs of the breast and the excised specimen were taken to confirm that excision was complete (Fig. 2A-
C). The patient was then placed in a supine position. Bleeding was stopped by electrocauterization when 
necessary. Small metallic clips were placed at the site of the lesion and the wound was closed with absorbable 
sutures. A pressure dressing was applied for 24 h. The average total procedure time was 70min and the patient 
was discharged after an observation period of 2h. 
When cancer was present, the pathologist reported on pathological type, size, grade and resection margins. Ink 
margins were considered negative when free of tumor. The presence of an extensive intraductal component 
(EIC) and/or lymphovascular invasion (LVI) and the results of immunohistochemical (IHC) analyses (estrogen-
progesterone receptors, c-erbB-2, Ki67, p53, hsp27) were also reported. 
For patients found to have a malignant lesion, further surgery was recommended. Open surgery was scheduled 
within the month following the ABBI procedure and involved complete re-excision of the biopsy site, even when 
the ABBI specimen-resection margins were negative for tumor, and axillary lymph-node dissection for invasive 
carcinoma. Radiation therapy was given after conservative surgery for invasive carcinoma or according to the 
Van Nuys prognostic index for ductal carcinoma in situ (DCIS).22 Adjuvant therapy was administered according 
to the recommendations of the 6th St Gallen International Consensus Conference.23 Twelve to 42 months of 
follow-up were available for the 61 ABBI patients. 
RESULTS 
Malignancy was confirmed in 27 (44%) of the 61 ABBI specimens (Table 1). The 27 mammographic lesions 
ranged in size from 5 to 15 mm (mean 8.5): 16 were masses, 9 had the appearance of microcalcifications, and 2 
were masses containing microcalcifications. Lesions were excised with a 15-mm cannula in 5 (19%) of the 27 
cases and a 20-mm cannula in 22 (81%). All 27 ABBI procedures were successful. In all cases, specimen and 
wound radiographs suggested complete excision of the lesion and the histological findings were consistent with 
the mammographic features. However, the mammographic size of the lesion was not predictive of the 
pathological size: for 16 (59%) of the 27 ABBI specimens, the size of the excised lesion differed by more than 2 
mm from the mammographic size. The 27 en block specimens enabled accurate histopathological 
characterization. Type, size, grade, resection margins, presence of EIC and/or LVI, and IHC test results were 
determined for all specimens. Clinically mild ecchymoses were common, but none of the patients experienced 
hematoma. One mild wound infection occurred, which was treated with oral antibiotics. 
Two patients whose en bloc biopsy specimens demonstrated carcinoma measuring < 1 cm and with negative 
margins more than 2 mm wide refused subsequent surgery and underwent radiotherapy: one was a 75-year-old 
patient whose ABBI specimen demonstrated low-grade 9-mm DCIS with negative margin widths larger than 2 
mm and the other, a 58-year-old patient whose ABBI specimen demonstrated low-grade 4-mm invasive ductal 
carcinoma (IDC) with negative margin more than 4 mm wide. One 80-year-old patient accepted re-excision, but 
did not undergo axillary dissection. Overall, 25 (93%) of the 27 biopsy sites were re-excised and 18 (95%) of the 
19 patients with invasive cancer underwent axillary lymph-node dissection. For all patients with carcinoma in 
situ in the ABBI biopsies, noninvasive disease was confirmed at surgery. The ABBI specimen margins were 
tumor free in 11 (41%) of the 27 patients diagnosed with carcinoma. None of the patients with tumor-free 
margins in the ABBI specimen was found to have residual disease at surgery. Finally, surgical re-excision 
confirmed residual tumor-free status in 64% (16/25) of the patients with malignant ABBI specimens. These 16 
patients were confirmed to be node-negative for invasive carcinoma, except one elderly patient who did not 
undergo axillary dissection. 
We calculated the probabilities that an ABBI specimen would have tumor-free margins and that complete 
excision would be achieved as a function of the mammographic or histological diameters of the cancer measured 
directly in the ABBI specimen (Table 2). Indeed, for nonpalpable breast cancer with a histological diameter less 
than 10 mm, the probability (92%) of obtaining complete resection was significantly better than the 
corresponding probability for larger lesions (P = 0.01 Fisher's exact test). 
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Table 1: mammographic features and histopathological findings in the ABBI specimen and at re-excision for the 
27 confirmed breast cancers 
Histopathological findings mammographic 
features and size ABBI specimen Surgical re—excision 
Mass, 5 mm IDC, 4 mm, margins – No additional surgery 
Mass, 6 mm IDC, 4 mm, margins – No residual tumor, 5N– 
Micro., 10 mm DCIS, 4 mm, margins + Residual DCIS, 5 mm 
Mass and micro., 10mm DCIS, 5 mm, margins – No residual tumor 
Mass, 6 mm IDC, 6 mm, margins – No residual tumor, 8N– 
Mass, 7 mm ILC, 6 mm, margins – No residual tumor, 14N– 
Mass, 8 mm CC, 6 mm, margins – No residual tumor, 14N– 
Mass, 8 mm IDC and DCIS, 6 mm, margins + No residual tumor, 7N– 
Micro., 10 mm DCIS, 6 mm, margins + No residual tumor 
Micro., 5mm DCIS, 8 mm, margins + No residual tumor 
Micro., 6mm DCIS, 8 mm, margins – No residual tumor 
Mass, 7 mm TC, 8 mm, margins – No residual tumor, 14N– 
Mass, 12 mm IDC and DCIS, 8 mm, margins + No residual tumor, 14N– 
Mass, 11 mm DCIS, 9 mm, margins – No additional surgery 
Micro., 10 mm IDC and DCIS, 10 mm, margins – No residual tumor, UN– 
Micro., 7mm DCIS, 10 mm, margins + No residual tumor 
Mass and micro., 7mm IDC, 10 mm, margins + No residual tumor, UN– 
Mass, 7 mm TC, 10 mm, margins + No residual tumor, 7N– 
Mass, 7 mm ILC, 10 mm, margins + Residual ILC, 4 mm, 7N– 
Mass, 10 mm IDC, 10 mm, margins + Residual DCIS, 1 mm, 1N + /22N
Mass, 15 mm IDC and DCIS, 10 mm, margins + Residual DCIS, 0,1 mm, 19N– 
Mass, 8 mm IDC, 12 mm, margins – No residual tumor,* 
Micro., 5mm IDC and DCIS, 12 mm, margins + Multifocal residual DCIS, 9N– 
Mass, 8 mm ILC, 12 mm, margins + Second lesion ILC, 8 mm, 18N– 
Micro., 10 mm IDC and DCIS, 18 mm, margins + Residual DCIS, 1 mm, 3N– 
Micro., 5mm DCIS, 20 mm, margins + Multifocal residual DCIS, 9N– 
Mass, 12 mm IDC, 20 mm, margins + Residual IDC, 2 mm, 12N– 
Abbreviations: Micro./micro., microcalcifications; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular 
carcinoma; TC, tubular carcinoma; CC, colloid carcinoma; N, axillary lymph node; —, negative; +, positive for tumor; margins —, negative 
margins for tumor; margins +, positive margins for tumor. 
*An 80-year-old patient, treated with lumpectomy and tamoxifen but no axillary dissection or radiotherapy. 
 
Table 2: Probabilities of the ABBI specimen having tumor-free margins and of complete excision as a function 
of the lesion diameter measured on mammography and in the pathological specimen 
Lesion diameter (mm) 
(n = 27) 
ABBI specimen with tumor-free 
margins 
(n = 27) 
No residual disease at re-excision 
(n = 25)* 
Mammography   
     <10(n = 17) 47% (8/17) 75% (12/16) 
     10-15 (n = 10) 30% (3/10) 44% (4/9) 
Pathological specimen   
     <10(n = 14) 64% (9/14) 92% (11/12) 
     10 or >10(n = 13) 15% (2/13) 38% (5/13) 
Two patients refused re-excision. 
Of the eight patients with DCIS alone, six (75%) underwent conservative surgery and radiation therapy. One 
(13%) of eight patients with extensive DCIS involving the margins of the re-excision tissue subsequently 
underwent mastectomy without axillary dissection and one (13%) of eight patients with recurrent disease 
underwent mastectomy rather than re-excision. Of the 19 patients with invasive disease, 17 (89%) underwent 
conservative surgery and radiation therapy. The two (11%) remaining patients with residual DCIS involving the 
margins of the re-excision tissue subsequently underwent mastectomy. One (6%) of the 18 patients who 
underwent axillary dissection had nodal metastases. 
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Overall, 23 (88%) of the 26 patients with primary breast cancer were treated with conservative surgery and three 
(12%) underwent mastectomy after re-excision of the ABBI biopsy site at which the attempt to obtain tumor-free 
margins had failed. 
A posteriori, the ABBI procedure was adequate (no residual disease at biopsy site, no axillary involvement) for 
locoregional surgical management in 63% (15/ 24) of the patients with malignant ABBI specimens and 92% 
(11/12) of the breast cancers measuring < 1cm found in this series of consecutive patients. The 12-42 months of 
follow-up available have been unremarkable for the 61 patients who underwent an ABBI procedure. 
DISCUSSION 
The basic principles of breast cancer surgery have evolved over the course of the 20th century. A certain number 
of experimental and clinical observations have invalidated Halsted's concept, according to which breast cancer 
necessarily progresses in successive steps from a local stage through an intermediary phase of regional extension 
to systemic involvement.24 The studies by Tubiana and Koscielny showed that metastatic potential developed 
when a tumor size of 1 mm was reached and that distant dissemination was not derived from the lymph nodes.25 
27 These findings have been confirmed by observations of metastases developing far distant from diagnosed 
cancers measuring less than 1 cm (10% at 10 years) or from cancers with tumor-negative axillary lymph nodes 
(30% at 10 years). An early diagnosis and tumor responsiveness to adjuvant therapies (hormonal and/or 
chemotherapy) are currently considered decisive elements in the prognosis for survival.23
Since the 1950s, extended radical mastectomy has gradually given way to modified radical mastectomy.28-30            
At present, mastectomy accounts for only 40-50% of the surgical interventions for breast cancer. So-called 
conservative breast surgery, i.e. quadrantectomy according to Veronesi et al.31 or lumpectomy according to 
Fischer et al.,32 combined with radiation therapy is recommended as first-line therapy for more than half the 
patients, provided that the margins of the excised tissue are tumor free. The main objectives of local treatment 
are complete excision with tumor-free margins and characterization of the prognostic and predictive factors that 
will guide the choices of systemic therapy. Axillary node surgery has also evolved in parallel with breast 
surgery, moving towards the concept of prognostic evaluation; for this the quality of the specimen takes priority 
over the number of nodes removed.33 35
The diagnostic characterization of NPBL has progressed markedly over the past years with the advent of 
stereoguided needle biopsy techniques that eliminate unnecessary surgical resection of benign lesions while 
carrying a low rate of missed cancers among the lesions not excised.5,36-40 Surgical management of these lesions 
should evolve with the primary objectives of improving localization and limiting tissue trauma. In an earlier 
study we confirmed that the ABBI method was a safe and accurate biopsy procedure.20 We established that an 
ABBI excision was feasible and adequate for less than 40% (17/43) of the benign lesions that would otherwise 
have been surgically excised in our department, and for only 21% (11/53) of the nonpalpable mammograhically 
detected carcinomas. Many (62%) of the excised NPBL in that study were not amenable to an ABBI procedure, 
primarily due to technical limitations. 
In this study, we calculated the probabilities of an excision having tumor-free margins and of a complete 
excision as a function of the lesion's diameter measured on mammography and in the ABBI specimen. To the 
best of our knowledge, no other investigation has examined these parameters. The probability of an ABBI 
procedure having excised a lesion completely, i.e., with no residual disease in the biopsy cavity, is approximately 
75% for malignant NPBL with a diameter of less than 10 mm on mammography. In the case of lesions with a 
radiographic diameter of 10-15 mm the probability of an adequate excision is less than 50%. Based on these 
estimations, we conclude that the complete-excision rate with an ABBI procedure for subclinical cancers can be 
improved by limiting the indications to suspicious lesions whose largest mammographic diameter is smaller than 
10 mm. When the largest diameter of the cancerous lesion measures less than 10 mm on the ABBI specimen, the 
probability of complete excision is higher than 90%. Above this threshold of 10 mm, the probability falls to 
about 40%. In light of these findings, to increase the chance of complete excision with tumor-free margins at the 
time of ABBI biopsy, we decided to immediately re-excise the biopsy bed before suturing the wound whenever 
the mammographic or macroscopic appearance of the specimen was highly suggestive of malignancy. 
In this larger series of subclinical breast cancers, we confirmed that complete excision of cancers smaller than 
1cm was possible with the ABBI procedure in around 90% of the selected cases.20 However, for invasive lesions 
we need to develop less invasive alternatives to lymph node dissection for prognostic axillary evaluation. The 
benefit of systematic lymph node dissection for all invasive lesions is now being questioned.41-44 The percentages 
of patients with axillary lymph node invasion by subclinical invasive lesions measuring less than 1 cm are low, 
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and the morbidity attributable to axillary node dissection is considerable.45,46 In addition, the current trend is to 
prescribe adjuvant therapy for the majority of patients, even when the axillary lymph nodes are free of metastatic 
disease.23 We think that this trend will become more widespread. It can be hoped that, in the future, further 
refinement of the histological prognostic characterizations of subclinical cancers less than 1 cm in size and DNA 
microarray analyses will definitively guide the therapeutic choices independently of axillary lymph node 
staging.47-52 In this context, the ABBI procedure performed under local anesthesia and radiological control could 
be envisaged as a supracon-servative alternative surgical means of achieving complete resection with tumor-free 
margins. While we await this hypothetical evolution, the technique of identifying the sentinel lymph node seems 
to be the most appropriate way of limiting the surgical trauma caused by axillary lymph node staging.33-35 
Recently, Haigh et al. demonstrated that a previous excisional biopsy did not compromise successful 
identification of the sentinel lymph node.53
Although the therapeutic perspectives for the ABBI method are limited at present by the small number of 
potential indications and the need for axillary lymph node staging for invasive lesions, this procedure may have a 
contributory role within the framework of the management of subclinical cancers. Stereotactic large-core breast 
biopsy, which is currently used to diagnose NPBL, provide fragmented tissue specimens and almost total 
disappearance of the tumor, when it is small.54-56 The mammographic disappearance of the lesion poses several 
problems when the lesion is malignant. The surgical intervention will not always be optimally guided by a clip at 
the center of the biopsy bed.54 Although the different IHC factors (homone receptors, proliferation markers, etc.) 
can be characterized in core biopsies, the architectural structure of the lesions may be lost to pathological 
analysis and thereby compromises the conclusions drawn (e.g., diagnosis of a small tubular carcinoma within a 
radial scar). In addition, the pathological diameters of small cancerous lesions, which are an important prognostic 
factor, cannot be correctly determined on the basis of percutaneous core biopsies.56 In contrast, examination of an 
ABBI specimen allows a precise pathological diagnosis, since the quality of the material is comparable to that 
obtained during surgical excision. Notably, among the 27 cancers identified in this series, only in 3 patients 
(12%) was a two-step surgical procedure performed. No patient with a lesion smaller than 1 cm underwent 
mastectomy, and no patient with in situ carcinoma was unnecessarily subjected to axillary lymph node 
dissection. For subclinical cancers measuring less than 1 cm, analysis of the results obtained with our classic 
surgical experience, without reference to our experience with the ABBI procedure, showed that two-step 
interventions were performed in 24% of cases, mastectomy in 10% and axillary lymph node dissection in 38% of 
those with DCIS, during the period from May 1994 to May 1998. This comparison suggests that surgical 
management of subclinical breast cancers under 1 cm in size is now better after an ABBI procedure. 
We suggest that the present approach represents a first step towards a surgical strategy that is better adapted to 
the pathological characteristics particular to these small tumors whose incidence is increasing and whose 
prognosis is generally excellent.57 The concept of supraconservative surgery will only be defensible as long as it 
respects the therapeutic requirements of conventional conservative surgery: that is to say, comparable 
percentages for locoregional recurrences, disease-free survival and overall survival, combined with better 
functional and esthetic results. 
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